Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 8, 2007

Catalyst and Wyeth Ink Agreements Worth Up To $100M

  • Catalyst Biosciences signed two agreements with Wyeth Pharmaceuticals with potential payments of up to $100 million plus royalties. The research collaboration and license agreements support discovery and preclinical development using Catalyst's Alterase™ therapeutics platform (engineered human proteases) directed at a target in metabolic disease and one in oncology.

    Wyeth will be responsible for the clinical development, manufacturing, and marketing of products developed as a result of these collaborations. The deal includes an upfront license payments, milestone payments, R&D funding, and royalties on product sales.

  • You’re all set! Thank you for subscribing to GEN Highlights.